Combination therapies targeting tumor-associated stroma or tumor cells

US11033621B2 · kind B2 · utility

Assignees

• Biomed Valley Discoveries, Inc. · US
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Saurabh Saha · Wellesley, US
• Xiaoyan Zhang · Lexington, US
• Dimiter S. Dimitrov · Frederick, US
• Zhongyu Zhu · Frederick, US
• Brad St. Croix · Frederick, US
• Enrique Zudaire · Germantown, US

Key dates

• Filing date: Jun 9, 2015
• Grant date: Jun 15, 2021
• Expiry date: Jun 9, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/507
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from the group consisting of an anti-angiogenic agent, a vascular disrupting agent (VDA), and combinations thereof; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided.